| Literature DB >> 28493547 |
Lara E Davis1, Katherine A Janeway2, Aaron R Weiss3, Yen-Lin E Chen4, Thomas J Scharschmidt5, Mark Krailo6, Julia L Glade Bender7, Lisa M Kopp8, Shreyaskumar R Patel9, Gary K Schwartz10, L Elise Horvath11, Douglas S Hawkins12, Meredith K Chuk13, Denise K Reinke14, Richard G Gorlick9, R Lor Randall15.
Abstract
More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016 issue of Cancer, several leaders in the field of sarcoma across disciplines gathered to discuss the status of sarcoma clinical research in AYAs. They determined that a focused effort to include the underrepresented and understudied AYA population in current and future sarcoma clinical trials is overdue. Trial enrichment for AYA-aged sarcoma patients will produce more meaningful results that better represent the disease's biology, epidemiology, and treatment environment. To address the current deficit, this commentary outlines changes believed to be necessary to expediently achieve an increase in the enrollment of AYAs in sarcoma clinical trials. Cancer 2017;123:3434-40.Entities:
Keywords: National Clinical Trials Network; adolescent; clinical trials; sarcoma; young adult
Mesh：
Year: 2017 PMID： 28493547 PMCID： PMC5650232 DOI： 10.1002/cncr.30757
Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860